[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657360":3},{"organization":4,"outcomesModule":7,"designInfo":127,"detailedDescription":133,"studyPopulation":126,"armGroups":134,"interventions":143,"overallOfficials":126,"centralContacts":126,"locations":126,"responsibleParty":149,"collaborators":126,"id":151,"slug":152,"hasResults":153,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":126,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":158,"minAge":159,"maxAge":126,"enrollmentInfo":160,"targetDuration":126,"studyType":163,"phases":164,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":172,"whyStopped":126,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":126},{"fullName":5,"class":6},"Jiangsu Hansoh Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":126},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Evaluation of PK parameters of HS-10504: Cmax","To evaluate the Cmax of HS-10504 in participants with hepatic impairment and normal hepatic function","216 hours after administration of HS-10504",{"measure":14,"description":15,"timeFrame":12},"Evaluation of PK parameters of HS-10504: AUC0-t","To evaluate the AUC0-t of HS-10504 in participants with hepatic impairment and normal hepatic function",{"measure":17,"description":18,"timeFrame":12},"Evaluation of PK parameters of HS-10504: AUC0-∞","To evaluate the AUC0-∞ of HS-10504 in participants with hepatic impairment and normal hepatic function",[20,23,26,29,32,35,38,41,44,47,50,53,56,59,61,64,68,72,75,78,81,84,87,90,93,96,99,102,105,108,111,114,117,120,123],{"measure":21,"description":22,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: Cmax.","To evaluate the Cmax of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":24,"description":25,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: AUC0-t.","To evaluate the AUC0-t of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":27,"description":28,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: AUC0-∞.","To evaluate the AUC0-∞ of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":30,"description":31,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: Tmax.","To evaluate the Tmax of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":33,"description":34,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: t1\u002F2z.","To evaluate the t1\u002F2z of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":36,"description":37,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: λz.","To evaluate the λz of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":39,"description":40,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: CL\u002FF.","To evaluate the CL\u002FF of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":42,"description":43,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: Vz\u002FF.","To evaluate the Vz\u002FF of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":45,"description":46,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: MRT0-t.","To evaluate the MRT0-t of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":48,"description":49,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: MRT0-∞","To evaluate the MRT0-∞ of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":51,"description":52,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: fu.","To evaluate the fu of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":54,"description":55,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: Cmax,Unbound.","To evaluate the Cmax,Unbound of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":57,"description":58,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: AUC0-t,Unbound.","To evaluate the AUC0-t,Unbound of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":60,"description":58,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2: AUC0-∞,Unbound.",{"measure":62,"description":63,"timeFrame":12},"Evaluation of PK parameters of HS-10504 and metabolite M6-2:CL\u002FF,Unbound .","To evaluate the CL\u002FF,Unbound of HS-10504 and metabolite M6-2 in participants with hepatic impairment and normal hepatic function",{"measure":65,"description":66,"timeFrame":67},"Adverse events","To evaluate the Occurrence of adverse events","Up to end of the study, approximately 3 months.",{"measure":69,"description":70,"timeFrame":71},"vital signs(blood pressure)","To evaluate the vital signs(blood pressure) of HS-10504 in participants with hepatic impairment and normal hepatic function","Up to end of the study, approximately 3 month.",{"measure":73,"description":74,"timeFrame":71},"vital signs( Pulse)","To evaluate the vital signs(Pulse) of HS-10504 in participants with hepatic impairment and normal hepatic function",{"measure":76,"description":77,"timeFrame":71},"vital signs(body temperature)","To evaluate the vital signs( body temperature) of HS-10504 in participants with hepatic impairment and normal hepatic function",{"measure":79,"description":80,"timeFrame":71},"Number of participants with clinical laboratory tests(complete blood count (CBC))","To evaluate the clinical laboratory tests(complete blood count (CBC)) of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":82,"description":83,"timeFrame":71},"Number of participants with urinalysis","To evaluate the abnormal of urinalysis of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":85,"description":86,"timeFrame":71},"Number of participants with abnormal blood chemistry","To evaluate the abnormal of blood chemistry of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":88,"description":89,"timeFrame":71},"Number of participants with abnormal coagulation tests","To evaluate the abnormal of coagulation tests of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":91,"description":92,"timeFrame":71},"12-lead electrocardiogram（ heart rate）","To evaluate the 12-lead electrocardiogram（heart rate） of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":94,"description":95,"timeFrame":71},"12-lead electrocardiogram（PR）","To evaluate the 12-lead electrocardiogram（PR） of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":97,"description":98,"timeFrame":71},"12-lead electrocardiogram（RR）","To evaluate the 12-lead electrocardiogram（RR） of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":100,"description":101,"timeFrame":71},"12-lead electrocardiogram（QRS duration）","To evaluate the 12-lead electrocardiogram（QRS duration） of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":103,"description":104,"timeFrame":71},"12-lead electrocardiogram（QTcF）","To evaluate the 12-lead electrocardiogram（ QTcF） of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":106,"description":107,"timeFrame":71},"Number of participants with abnormal general inspection","To evaluate the abnormal of general inspection of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":109,"description":110,"timeFrame":71},"Number of participants with abnormal head and neck","To evaluate the abnormal of head and neck of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":112,"description":113,"timeFrame":71},"Number of participants with abnormal lymph nodes","To evaluate the abnormal of lymph nodes of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":115,"description":116,"timeFrame":71},"Number of participants with abnormal chest","To evaluate the abnormal of chest of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":118,"description":119,"timeFrame":71},"Number of participants with abnormal abdomen","To evaluate the abnormal of abdomen of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":121,"description":122,"timeFrame":71},"Number of participants with abnormal spine and extremities","To evaluate the abnormal of spine and extremities of HS-10504 in participants with hepatic impairment and normal hepatic function.",{"measure":124,"description":125,"timeFrame":71},"Number of participants with abnormal neurological examination","To evaluate the abnormal of neurological examination of HS-10504 in participants with hepatic impairment and normal hepatic function.",null,{"allocation":128,"interventionModel":129,"interventionModelDescription":126,"primaryPurpose":130,"observationalModel":126,"timePerspective":126,"maskingInfo":131},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":132,"maskingDescription":126,"whoMasked":126},"NONE","In each part, two treatment groups were set up (Group A: participants with moderate hepatic impairment; Group B: participants with normal hepatic function), and 8 participants (both males and females) were enrolled in each group. On Day 1, a single oral dose of 400 mg HS-10504 tablet was administered in the fasting state.",[135,140],{"label":136,"type":137,"description":126,"interventionNames":138},"Participants with hepatic impairment","EXPERIMENTAL",[139],"Drug: HS-10504",{"label":141,"type":137,"description":126,"interventionNames":142},"Participants with normal hepatic function",[139],[144],{"type":145,"name":146,"description":147,"armGroupLabels":148,"otherNames":126},"DRUG","HS-10504","HS-10504:On Day 1, a single oral dose of 400 mg HS-10504 tablet was administered in the fasting state.",[136,141],{"type":150,"investigatorFullName":126,"investigatorTitle":126,"investigatorAffiliation":126,"oldNameTitle":126,"oldOrganization":126},"SPONSOR","100657360","phase-1-a-pharmacokinetic-study-of-hs-10504-in-participants-with-hepatic-impairment-and-normal-hepatic-function-100657360",false,"NCT07836504","A Pharmacokinetic Study of HS-10504 in Participants With Hepatic Impairment and Normal Hepatic Function.","Inclusion Criteria:\n\n* All participants must meet ALL of the following criteria to be eligible for this study:\n\n  1. Provide written informed consent before any study related procedures, have a full understanding of the study, its procedures, and possible adverse events, and express a willingness and ability to comply with the protocol requirements.\n  2. Be male or female adults.\n  3. Agree to practice highly effective contraception from the time of signing the informed consent form until 6 months after the last dose of study drug (only non pharmacological contraceptive measures are allowed during the study), and refrain from attempting to conceive or donate sperm\u002Feggs during this period.\n\nParticipants with normal hepatic function must meet the following criterion to be eligible for this study:\n\n1\\. Participants in the normal hepatic function group should be matched with those in the hepatic impairment group for body mass index (BMI), age, and sex.\n\nParticipants with hepatic impairment must meet the following criteria to be eligible for this study:\n\n1. Chronic liver injury caused by primary liver disease;\n2. The investigator judges that the participant's hepatic function status is stable based on the participant's clinical symptoms and other available examination results at screening;\n3. Have had a stable medication regimen for the treatment of hepatic impairment, complications, and other concomitant diseases for at least 14 days prior to administration of the investigational product, with no need for dose adjustment; or have not been on any such medication.\n\nExclusion Criteria:\n\n* Participants who meet any of the following criteria will not be enrolled in this study:\n\n  1. Have participated in any other clinical trial and used any investigational drug\u002Fdevice within 3 months prior to screening;\n  2. Have a history of surgery within 3 months prior to screening, or have planned surgery during the study period, or have undergone surgery that may affect drug absorption, distribution, metabolism, or excretion;\n  3. Have experienced significant blood loss or blood donation within 3 months prior to screening, or blood loss ≥200 mL within 1 month, or have planned blood donation during the study period;\n  4. Have used strong or moderate inhibitors or inducers of CYP3A4\u002F5, CYP2C8, and CYP2D6 within 30 days prior to the first dose of the investigational product, or have used albumin within 14 days prior to the first dose;\n  5. Have a history of, or currently have, severe diseases of the nervous, psychiatric, digestive, circulatory, respiratory, urinary systems, etc., or have developed a new illness before administration of the investigational product, which is assessed by the investigator as unsuitable for participation in this study;\n  6. Have a history of severe allergy, are prone to allergic reactions, or have an allergic constitution, or are known to be allergic to any component of the investigational product;\n  7. Have regularly consumed alcohol within 3 months prior to screening or are unable to refrain from alcohol consumption during the study period, or have a positive alcohol breath test at screening;\n  8. Have smoked an average of \\>5 cigarettes per day within 3 months prior to screening, or are unable to refrain from using any tobacco products during the study period;\n  9. Have consumed excessive amounts of tea, coffee, and\u002For caffeinated beverages within 3 months prior to screening;\n  10. Have a history of drug abuse, drug dependence, or illicit drug use within 5 years prior to screening, or have a positive drug abuse screening test;\n  11. Are lactating women within 1 month prior to screening or during the study period, or have a positive pregnancy test;\n  12. Have had unprotected sexual intercourse within 14 days prior to screening;\n  13. Have special dietary requirements, are unable to comply with a uniform diet, or have difficulty swallowing;\n  14. Are unable to tolerate venipuncture or indwelling needle blood sampling, or have a history of needle phobia or blood phobia;\n  15. Are unable to complete the study for other reasons, or are judged by the investigator as unsuitable for participation.\n\nParticipants with normal hepatic function who meet any of the following exclusion criteria will be excluded:\n\n1. History of hepatic impairment;\n2. Clinically significant abnormalities in physical examination, vital signs, 12 lead ECG, or clinical laboratory tests at screening that are judged by the investigator as unsuitable for enrollment;\n3. Use of any prescription drugs, over the counter drugs, herbal medicines, or health supplements within 14 days prior to the first dose of the investigational product, or use of any drug without a washout period of at least 7 half lives.\n\nParticipants with hepatic impairment who meet any of the following exclusion criteria will be excluded:\n\n1. The participant has any of the following conditions that, in the investigator's assessment, makes them unsuitable for participation in this trial: ① history of liver transplantation; ② history of partial hepatectomy; ③ suspected or confirmed hepatocellular carcinoma or other malignancies; ④ hepatic failure; ⑤ bleeding from esophageal and gastric varices within 3 months prior to screening; ⑥ diseases such as biliary cirrhosis or extrahepatic biliary obstruction; ⑦ coexisting overt hepatic encephalopathy, refractory ascites, or hepatorenal syndrome.\n2. Apart from the primary liver disease itself, the participant has a history of or currently has other severe systemic organ diseases or clinically significant laboratory abnormalities that, in the investigator's judgment, make them unsuitable for participation in this trial.",true,"ALL","18 Years",{"count":161,"type":162},32,"ESTIMATED","INTERVENTIONAL",[165],"PHASE1","This is a two-part single-center, open-label, parallel, single-dose pharmacokinetic study of HS-10504 in participants with hepatic impairment and normal hepatic function.",[168],"To Compare the Pharmacokinetic (PK) Differences of HS-10504 Between Participants With Hepatic Impairment and Participants With Normal Hepatic Function",[170,171,146],"Phase I","Hepatic impairment","NOT_YET_RECRUITING","2026-09-22",{"date":175,"type":176},"2026-09-23","ACTUAL",{"date":178,"type":162},"2026-09-30",{"date":180,"type":162},"2027-10-30",{"name":5,"class":6}]